H.C. Wainwright lifted its price target on shares of Cingulate (NASDAQ: CING) to $20.00, a significant increase from the previous target of $8.00. The firm has maintained a Buy rating on the stock, ...

H.C. Wainwright raised the firm’s price target on Cingulate (CING) to $20 from $8 and keeps a Buy rating on the shares to reflect the recent ...

KANSAS CITY, Kan., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products.

New ADHD Medication Is On Track For NDA Filing Within A Year – Hear From This Biotech's CEO What's Going On With Cingulate Shares Recently? Cingulate Inc. (NASDAQ: CING) shares are soaring Friday.

Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug ...

As of December 23, 2024, the average one-year price target for Cingulate is $61.46/share. The forecasts range from a low of $8.08 to a high of $100.80. The average price target represents an ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...